Two easy millionaire-maker stocks?

Could these stocks help you make a million with little effort?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in Neil Woodford favourite ReNeuron Group (LSE: RENE) jumped in early deals this morning after the company announced a positive result from its Phase II clinical trial of its CTX cell therapy candidate for stroke disability. 

It looks as if the trial was a major success, paving the way for further testing and development of the product. Indeed, the study showed that the “positive response rates in key measures reported at three months after treatment in the PISCES II clinical trial were sustained at 12 months after treatment.” 

The trial also revealed that the “CTX treatment was well tolerated in both short and longer term follow-up.” 

According to the company, these findings are “highly encouraging” as they indicate that the CTX therapy has the “potential to produce meaningful and sustained improvements in disability as well as motor function in disabled stroke patients.” No other treatments with a similar goal exist. 

Development takes time

There’s still much work to do before CTX is a commercial success, but so far, findings are pointing to the conclusion that this treatment will not disappoint — great news for investors. 

Getting new treatments from the development to commercial stage is a complex, timely and costly process. Luckily it looks as if Reneuron is making substantial progress, and more importantly, the business is well-funded and supported by stakeholders. To help fund its development the company recently received a grant of £1.2m from the Welsh Government.  

Reneuron isn’t going to make its shareholders rich overnight, although, over the long term, I believe the sky is the limit for the company. 

Figures show that the annual health and social costs of caring for these patients is estimated to be more than £5bn in the UK and over $70bn in the US. If the firm’s treatment can help control these costs and improve patient quality of life, taking just a tiny share of this market could be a multi-billion pound opportunity for the company. 

Slow and steady 

Reneuron could eventually see sales of more than £1bn, but for investors who are looking for a more defensive investment, Amino Technologies (LSE: AMO) might be a better buy. 

Amino is a cash cow and management is committed to returning as much to investors as possible. Over the past five years, the firm has paid out around 22p per share in dividends to investors, which works out at around 44% of the year-end 2012 share price of 50p. Including dividends, over the past five years, the shares have returned 316%, smashing the FTSE 250’s performance over the same period of 70%. 

If Amino can keep up this steady performance, shareholders will get rich slowly. Right now the shares support a dividend yield of 3.6%, the payout is covered 2.3 times by earnings per share and the shares trade at a forward P/E of 13.3. For the fiscal year ending 30 November 2018, analysts have pencilled in a dividend per share of 7.3p giving a dividend yield of 4%. Earnings per share growth of 8% should give a forward P/E of 12.3. 

Overall, if you’re looking for a low-risk income and growth stock to help you make a million, I believe that you can’t go wrong with Amino. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

These were the FTSE 100’s dogs and stars in February

The FTSE 100 limped along last month, but some Footsie shares soared while others slumped. Here are February's winners and…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

This £43bn of passive income is up for grabs today!

As a lover of passive income, I'm always on the lookout for extra cash. The good news is that these…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

Is this my once-in-a-decade chance to buy these 2 beaten-down UK shares before they rocket?

The FTSE 100 has had a bumpy ride but these two UK shares have had it bumpier. Could now be…

Read more »

Young black man looking at phone while on the London Overground
Investing Articles

£6k bought me 3,093 shares in this overlooked FTSE passive income stock yielding 9.1% a year

This FTSE 100 dividend stock pays one of the most generous levels of passive income on the index, yet often…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

With a 5.35% yield does it matter if the National Grid share price never rises again?

The National Grid share price will never fly to the stars, but given the regular supply of dividends it offers,…

Read more »

Risk reward ratio / risk management concept
Investing Articles

Here’s why I think the Lloyds share price is undervalued but still not worth me buying

Oliver Rodzianko reckons the Lloyds share price is not appealing enough for him to make a long-term value investment in…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Insiders are buying Rolls-Royce shares! Should I do the same

Two directors have been buying Rolls-Royce shares since the start of the year. Does that mean the rally has further…

Read more »

Senior woman potting plant in garden at home
Investing Articles

How I’d invest a £100K SIPP to target £8K in dividends annually

Christopher Ruane sets out some principles he adopts when investing his SIPP and explains how he would aim for a…

Read more »